Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

CYAD 01

Next Previous
Search
Drug Profile

CYAD 01

Alternative Names: CAR NKG2D; CAR-T NKG2D; CAR-T NKR-2; CM-CS-1; CYAD-01; NKG2D-CAR-T-cells; NKR 2 T-cell; NKR-2; NKR-2 CAR-T Cells; NKR-2 T-cell immunotherapy; NKR-2-T-cell-therapy; NKR-T cells

Latest Information Update: 08 Mar 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Dartmouth College
  • Developer Celyad Oncology; Dana-Farber Cancer Institute; Novella Clinical
  • Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies; T lymphocyte cell therapies
  • Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Multiple myeloma; Solid tumours
  • No development reported Colorectal cancer
  • Discontinued Acute myeloid leukaemia; Myelodysplastic syndromes

Most Recent Events

  • 28 Feb 2024 Celyad terminates a phase I LINK trial for Colorectal cancer (Late-stage disease) in Belgium due to difficulties in patient recruitment and clinical strategy modification based on new clinical data generated in the NKR-2 early development (SC), prior to February 2024 (NCT03370198)
  • 22 Jun 2021 Celyad has patents protection for chimeric natural killer cell receptors, NKR CAR-T cells and methods of treating cancer with these NKR CAR-T cells, In USA, In licensed from Dartmouth
  • 28 Feb 2021 Celyad has two patents pending applications for chimeric natural killer cell receptors, NKR CAR-T cells and methods of treating cancer with these NKR CAR-T cells, In USA, In licensed from Dartmouth

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top